[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1124037T1 - Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης - Google Patents

Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης

Info

Publication number
CY1124037T1
CY1124037T1 CY20201101050T CY201101050T CY1124037T1 CY 1124037 T1 CY1124037 T1 CY 1124037T1 CY 20201101050 T CY20201101050 T CY 20201101050T CY 201101050 T CY201101050 T CY 201101050T CY 1124037 T1 CY1124037 T1 CY 1124037T1
Authority
CY
Cyprus
Prior art keywords
preparation
microspherds
controlled release
release characteristics
peptide loaded
Prior art date
Application number
CY20201101050T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthymios Koutris
Katerina MINIOTI
Sotiria Chaitidou
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Publication of CY1124037T1 publication Critical patent/CY1124037T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Νέα μέθοδος για την παρασκευή ενέσιμης σύνθεσης μακράς δράσης, που βασίζεται επί βιοαποικοδομήσιμων μικροσφαιριδίων πολυ(D,L-λακτιδίου-συν-γλυκολιδίου), που περιλαμβάνουν δραστικά φαρμακευτικά συστατικά πεπτιδίου.
CY20201101050T 2014-03-31 2020-11-09 Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης CY1124037T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/000858 WO2015149820A1 (en) 2014-03-31 2014-03-31 Preparation of peptide loaded plga microspheres with controlled release characteristics

Publications (1)

Publication Number Publication Date
CY1124037T1 true CY1124037T1 (el) 2022-03-24

Family

ID=50486884

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101050T CY1124037T1 (el) 2014-03-31 2020-11-09 Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης

Country Status (22)

Country Link
US (1) US9943483B2 (el)
EP (1) EP3125871B1 (el)
JP (1) JP6494657B2 (el)
KR (1) KR102218655B1 (el)
CN (2) CN106170284A (el)
AU (1) AU2014389015B2 (el)
BR (1) BR112016022550B1 (el)
CA (1) CA2944561C (el)
CY (1) CY1124037T1 (el)
DK (1) DK3125871T3 (el)
EA (1) EA032580B1 (el)
ES (1) ES2837044T3 (el)
HR (1) HRP20210058T1 (el)
HU (1) HUE052289T2 (el)
LT (1) LT3125871T (el)
MX (1) MX371139B (el)
PL (1) PL3125871T3 (el)
PT (1) PT3125871T (el)
RS (1) RS61209B1 (el)
SI (1) SI3125871T1 (el)
WO (1) WO2015149820A1 (el)
ZA (1) ZA201607413B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439594B2 (en) 2012-12-04 2022-09-13 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
CN107106499B (zh) * 2014-11-02 2021-09-17 纳诺精密医疗有限公司 用于延长释放治疗剂的可植入医药装置
KR102068578B1 (ko) * 2016-08-16 2020-01-21 중앙대학교 산학협력단 세포전달을 위한 다공성 마이크로스피어 및 이의 제조방법
JP2020513420A (ja) * 2016-12-12 2020-05-14 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
CN108113975B (zh) * 2018-02-02 2020-10-09 中国人民解放军军事科学院军事医学研究院 一种基于涡漩振荡器的plga微球制备方法及其应用
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
CN109106688B (zh) * 2018-08-22 2021-08-17 丽珠医药集团股份有限公司 一种醋酸奥曲肽微球的制备方法
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법
JP2021147329A (ja) * 2020-03-16 2021-09-27 株式会社リコー 粒子の製造方法
JP6810502B1 (ja) * 2020-05-08 2021-01-06 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
KR20220163417A (ko) * 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 주제가 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
WO2021224999A1 (ja) * 2020-05-08 2021-11-11 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116139256A (zh) * 2023-03-14 2023-05-23 复旦大学附属肿瘤医院 生长抑素/生长抑素类似物缓释膜及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
US8808746B2 (en) * 2004-04-30 2014-08-19 Fresenius Kabi Usa, Llc Sustained-release microspheres and methods of making and using same
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels

Also Published As

Publication number Publication date
EA201691884A1 (ru) 2017-02-28
MX371139B (es) 2020-01-20
CN114191538A (zh) 2022-03-18
JP6494657B2 (ja) 2019-04-03
EP3125871B1 (en) 2020-10-21
HUE052289T2 (hu) 2021-04-28
RS61209B1 (sr) 2021-01-29
PL3125871T3 (pl) 2021-04-19
DK3125871T3 (da) 2020-12-21
KR102218655B1 (ko) 2021-02-22
ZA201607413B (en) 2018-11-28
US20170281547A1 (en) 2017-10-05
WO2015149820A1 (en) 2015-10-08
SI3125871T1 (sl) 2021-03-31
MX2016012846A (es) 2017-05-09
AU2014389015B2 (en) 2019-05-09
CA2944561C (en) 2019-06-18
EP3125871A1 (en) 2017-02-08
BR112016022550B1 (pt) 2023-03-28
ES2837044T3 (es) 2021-06-29
AU2014389015A1 (en) 2016-09-29
CN106170284A (zh) 2016-11-30
LT3125871T (lt) 2020-12-28
CA2944561A1 (en) 2015-10-08
KR20160137608A (ko) 2016-11-30
BR112016022550A2 (el) 2017-08-15
EA032580B1 (ru) 2019-06-28
PT3125871T (pt) 2021-01-06
JP2017509661A (ja) 2017-04-06
HRP20210058T1 (hr) 2021-03-05
US9943483B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
CY1124037T1 (el) Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης
NI201800038S (es) Dispositivo de administración de medicamento intranasal
CY1123720T1 (el) Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος
DOP2017000280A (es) Formas administración sólidas de palbociclib
HK1252531A1 (zh) 用於藥物遞送的具有滲透增强劑的組合物
CL2014003215A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion
CL2014003216A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion.
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
CU20160164A7 (es) Un nanocomplejo micelar
IL254813B (en) Sustained-release injectable formulations containing isoxazoline active agent and methods and uses thereof
DK2964244T3 (da) Modificerede poly(beta-aminoestere) til lægemiddelafgivelse
DK3357491T3 (da) Farmaceutisk sammensætning til afgivelse af et anionisk medikament
DK3518892T3 (da) Farmaceutisk formulering, der indeholder en insulinforbindelse
PH12016501841A1 (en) Immunosuppressant formulation
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
EP3310800A4 (en) ADMINISTRATION SYSTEMS FOR CONTROLLED RELEASE OF MEDICAMENTS
CY1123022T1 (el) Σταθερες φαρμακευτικες συνθεσεις που περιεχουν σιταγλιπτινη υπο τη μορφη δισκιων αμεσης απελευθερωσης
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
EP3448360A4 (en) BIODEGRADABLE MICROSPHERIC COMPOSITIONS FOR PARENTERAL ADMINISTRATION
BR112016016297A2 (pt) Aparelho para cortar um polímero superabsorvente, e método para preparar um polímero superabsorvente
EP3377011A4 (en) LASER-ASSISTED MEDICAMENT DELIVERY SYSTEM
EP3373977A4 (en) CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE